Screening & Prevention — MCQs
On this page
A 58-year-old woman attends for her NHS breast screening mammogram. The report shows scattered fibroglandular densities (approximately 40% of breast tissue). She asks what this means for her breast cancer risk and whether additional screening is needed. What is the most appropriate advice?
A 60-year-old woman with a 35 pack-year smoking history attends for cardiovascular risk assessment. She quit smoking 6 months ago. Her BP is 138/82 mmHg, BMI 27 kg/m², total cholesterol 6.2 mmol/L, HDL 1.3 mmol/L, and non-HDL 4.9 mmol/L. Her QRISK3 score is 12%. She asks about lung cancer screening as her friend in the United States receives annual CT scans. What is the most appropriate response?
A 74-year-old man attends following a routine blood test which shows a PSA of 6.2 ng/mL. He is asymptomatic with no urinary symptoms and has an unremarkable prostate on digital rectal examination. He asks whether he needs further investigation. What is the most appropriate management?
A 26-year-old woman attends for cervical screening. She reports being in a monogamous relationship with a female partner for 3 years. She has never had sexual contact with men and is concerned that cervical screening may not be necessary for her. What is the most appropriate advice regarding cervical screening?
A 44-year-old woman with a BMI of 38 kg/m², polycystic ovary syndrome, and gestational diabetes in two previous pregnancies attends for weight management. She has lost 3 kg over 6 months with lifestyle modification. Her fasting glucose is 5.8 mmol/L and HbA1c is 41 mmol/mol. What is her current diabetes risk status and most appropriate preventive management?
A 67-year-old woman with type 2 diabetes attends for review. Her diabetic eye screening result indicates 'ungradable images - unable to visualise retina due to cataracts'. The report requests referral to ophthalmology. She mentions her vision has gradually deteriorated but she can still manage daily activities. What is the most appropriate management?
A 35-year-old man presents requesting a general health check. He has no symptoms and takes no regular medication. His father developed hypertension at age 60. The patient runs regularly and maintains a healthy diet. His BMI is 24 kg/m², blood pressure 118/76 mmHg. He asks for blood tests 'to check everything is okay'. What is the most appropriate approach?
A 49-year-old woman attends for discussion about her recent NHS breast screening mammogram which showed scattered fibroglandular densities. She has read online that dense breast tissue increases cancer risk and asks whether she needs additional screening with ultrasound or MRI. What is the most appropriate response based on current NHS screening policy?
A 52-year-old woman of South Asian ethnicity attends for her NHS Health Check. She has a BMI of 26 kg/m², waist circumference 82 cm, blood pressure 128/78 mmHg, fasting glucose 6.3 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.1 mmol/L. She has no family history of diabetes. What is her diabetes risk status?
A 66-year-old man has completed 12 weeks of varenicline for smoking cessation and reports being smoke-free for 10 weeks. He works as a long-distance lorry driver and is concerned about weight gain since quitting (he has gained 4 kg). He requests to continue varenicline for another 12 weeks to prevent relapse. What is the most appropriate response?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 71: A 58-year-old woman attends for her NHS breast screening mammogram. The report shows scattered fibroglandular densities (approximately 40% of breast tissue). She asks what this means for her breast cancer risk and whether additional screening is needed. What is the most appropriate advice?
- A. Breast density does not affect cancer risk; routine triennial screening is appropriate
- B. Dense breast tissue increases cancer risk modestly but NHS screening intervals remain unchanged (Correct Answer)
- C. She should have annual MRI screening in addition to mammography
- D. She should have ultrasound screening every 6 months
- E. She should be referred to genetics for assessment of familial risk
Explanation: ***Dense breast tissue increases cancer risk modestly but NHS screening intervals remain unchanged*** - High **breast density**, particularly with **fibroglandular tissue**, is an independent, modest risk factor for breast cancer and can also **mask small tumors** on mammograms. - Despite this increased risk, current **NHS Breast Screening Programme** guidelines maintain standard **triennial screening** (every 3 years) for women with scattered fibroglandular densities, without recommending shorter intervals or supplemental imaging. *Breast density does not affect cancer risk; routine triennial screening is appropriate* - This statement is incorrect as higher **breast density** is a well-established, independent **risk factor** for developing breast cancer. - While routine triennial screening is appropriate for this patient, it is crucial to accurately inform her that breast density *does* modestly **increase her risk**. *She should have annual MRI screening in addition to mammography* - **Annual MRI screening** is typically reserved for women at very high risk of breast cancer, such as those with **BRCA gene mutations** or a lifetime risk exceeding 30%. - Scattered fibroglandular densities (40% breast tissue) do not meet the criteria for routine supplemental MRI surveillance in the absence of other high-risk factors. *She should have ultrasound screening every 6 months* - There is no clinical evidence or national guideline supporting **6-monthly ultrasound** screening for asymptomatic women based solely on scattered breast density. - While ultrasound can be a useful adjunct in diagnostic workups for dense breasts, it is not a **standardized primary screening tool** in the UK for women at average risk. *She should be referred to genetics for assessment of familial risk* - Referral to **genetics** for familial risk assessment is indicated by a significant **family history** of breast/ovarian cancer (e.g., multiple affected first-degree relatives, young-onset cancer). - **Mammographic breast density** alone is a common finding and is not a direct indicator for genetic testing or a hereditary cancer syndrome referral.
Question 72: A 60-year-old woman with a 35 pack-year smoking history attends for cardiovascular risk assessment. She quit smoking 6 months ago. Her BP is 138/82 mmHg, BMI 27 kg/m², total cholesterol 6.2 mmol/L, HDL 1.3 mmol/L, and non-HDL 4.9 mmol/L. Her QRISK3 score is 12%. She asks about lung cancer screening as her friend in the United States receives annual CT scans. What is the most appropriate response?
- A. Arrange annual low-dose CT chest scan as she meets high-risk criteria
- B. Explain that lung cancer screening with CT is not part of the NHS national screening programme (Correct Answer)
- C. Refer her to respiratory medicine for consideration of CT screening
- D. Arrange a chest X-ray now and annually for the next 5 years
- E. Advise CT screening only if she develops respiratory symptoms
Explanation: ***Explain that lung cancer screening with CT is not part of the NHS national screening programme*** - In the UK, a universal **national screening programme** for lung cancer using low-dose CT (LDCT) scans is not currently implemented by the **NHS National Screening Committee**. - While **Targeted Lung Health Checks** are being piloted in specific high-risk areas, routine, nationwide access to LDCT screening for asymptomatic patients is not standard NHS practice. *Arrange annual low-dose CT chest scan as she meets high-risk criteria* - Despite the patient meeting high-risk criteria often used in international trials (e.g., **NLST**), clinicians in UK primary care cannot routinely arrange **low-dose CT (LDCT)** for screening purposes outside of official pilot programs or research. - **NICE guidelines** in the UK do not currently recommend widespread lung cancer screening with CT as a standard primary care intervention for all former heavy smokers. *Refer her to respiratory medicine for consideration of CT screening* - Referral to secondary care for **asymptomatic screening** is inappropriate given that no national program exists, and it would place an unnecessary burden on specialist services. - Respiratory physicians follow the same **national guidelines** which do not currently support ad-hoc CT screening for asymptomatic individuals outside of specific initiatives. *Arrange a chest X-ray now and annually for the next 5 years* - **Chest X-rays** have been proven ineffective in reducing lung cancer mortality when used as a screening tool in multiple large clinical trials. - They are associated with **high false-negative rates** for early-stage disease and contribute to unnecessary **radiation exposure** without a proven screening benefit. *Advise CT screening only if she develops respiratory symptoms* - A CT scan performed for the development of respiratory symptoms is considered a **diagnostic investigation**, not a screening tool, and should follow **Two Week Wait (2WW) cancer referral pathways**. - If symptoms such as **persistent cough** or **haemoptysis** arise, the initial investigation is typically a **chest X-ray**, followed by a diagnostic CT if indicated, not a screening CT.
Question 73: A 74-year-old man attends following a routine blood test which shows a PSA of 6.2 ng/mL. He is asymptomatic with no urinary symptoms and has an unremarkable prostate on digital rectal examination. He asks whether he needs further investigation. What is the most appropriate management?
- A. Arrange urgent urology referral for prostate biopsy
- B. Repeat PSA in 1 month and refer if persistently elevated
- C. Discuss the implications and arrange shared decision-making about further investigation (Correct Answer)
- D. Reassure him that PSA elevation is normal at his age and no action needed
- E. Start a trial of alpha-blocker therapy and recheck PSA in 3 months
Explanation: ***Discuss the implications and arrange shared decision-making about further investigation***- PSA testing is not part of a formal **screening program** because it can lead to **overdiagnosis** and treatment of non-clinically significant disease, especially in older patients.- Management must involve **shared decision-making**, weighing the elevated PSA against his life expectancy, potential treatment side effects, and his personal preferences.*Arrange urgent urology referral for prostate biopsy*- An **urgent referral** (using the 2-week wait pathway) is often triggered by a PSA > 5.0 ng/mL in this age group, but it should only occur after a thorough discussion of the **risks and benefits**.- Primary care practitioners must first explore the patient's wishes as **prostate biopsy** and subsequent treatments carry significant morbidity that may not benefit a 74-year-old.*Repeat PSA in 1 month and refer if persistently elevated*- While repeating a PSA can rule out transient elevation from **prostatitis** or recent ejaculation, it does not address the fundamental need for **patient counseling** regarding the initial result.- In an asymptomatic patient with an unremarkable **digital rectal examination (DRE)**, the priority is discussing the clinical significance of the current result rather than just delaying the decision.*Reassure him that PSA elevation is normal at his age and no action needed*- A PSA of 6.2 ng/mL is technically above the **age-specific reference range** (usually < 5.0 ng/mL for men in their 70s) and cannot be dismissed as entirely "normal."- Completely ignoring the result fails to provide the patient with the information needed to make an **informed choice** about his health care.*Start a trial of alpha-blocker therapy and recheck PSA in 3 months*- **Alpha-blockers** are used to treat **lower urinary tract symptoms (LUTS)** associated with BPH, but this patient is explicitly described as **asymptomatic**.- Using medication to treat a laboratory value without clinical indication is inappropriate and delays the necessary **diagnostic discussion** regarding possible malignancy.
Question 74: A 26-year-old woman attends for cervical screening. She reports being in a monogamous relationship with a female partner for 3 years. She has never had sexual contact with men and is concerned that cervical screening may not be necessary for her. What is the most appropriate advice regarding cervical screening?
- A. She does not need cervical screening as she has no risk of HPV transmission
- B. She should attend for routine cervical screening as per national guidelines (Correct Answer)
- C. She only needs cervical screening if she develops symptoms
- D. She should have cervical screening every 5 years instead of 3 years
- E. She should be tested for HPV antibodies before deciding about screening
Explanation: ***She should attend for routine cervical screening as per national guidelines*** - All individuals with a **cervix** aged 25–64 should participate in screening, regardless of their sexual history or orientation, as **Human Papillomavirus (HPV)** can be transmitted between female partners. - Transmission can occur through **skin-to-skin** genital contact, digital-vaginal contact, or the sharing of **sex toys**, making screening essential for women who have sex with women (WSW). *She does not need cervical screening as she has no risk of HPV transmission* - This is a common misconception; while the risk may vary, **HPV transmission** is well-documented between female partners through non-penetrative contact. - Medical guidelines explicitly state that **sexual orientation** should not be used as a reason to opt-out of the screening program. *She only needs cervical screening if she develops symptoms* - Cervical screening is a **preventative tool** designed to detect asymptomatic **pre-cancerous changes** (cervical intraepithelial neoplasia) before they progress to cancer. - Waiting for symptoms, such as **abnormal vaginal bleeding**, often means the disease has already progressed to a later, more dangerous stage. *She should have cervical screening every 5 years instead of 3 years* - Screening intervals are determined by **age and clinical findings**, not by the gender of sexual partners; the standard interval for a 26-year-old is every **3 years**. - Deviating from **national guidelines** based on perceived low risk can lead to missed diagnoses of high-risk HPV strains. *She should be tested for HPV antibodies before deciding about screening* - **Serological testing** for HPV antibodies is not a substitute for cervical screening as it does not indicate current infection or the presence of **cytological abnormalities**. - The screening program relies on **primary HPV DNA testing** from a cervical swab, and an antibody test would provide no actionable information for cancer prevention.
Question 75: A 44-year-old woman with a BMI of 38 kg/m², polycystic ovary syndrome, and gestational diabetes in two previous pregnancies attends for weight management. She has lost 3 kg over 6 months with lifestyle modification. Her fasting glucose is 5.8 mmol/L and HbA1c is 41 mmol/mol. What is her current diabetes risk status and most appropriate preventive management?
- A. Low risk; continue lifestyle advice and screen for diabetes every 3 years
- B. Moderate risk; arrange annual HbA1c monitoring
- C. High risk; refer to NHS Diabetes Prevention Programme even without non-diabetic hyperglycaemia (Correct Answer)
- D. Very high risk; commence metformin for diabetes prevention
- E. Diabetes likely given risk factors; arrange oral glucose tolerance test
Explanation: ***High risk; refer to NHS Diabetes Prevention Programme even without non-diabetic hyperglycaemia*** - Patients with a history of **gestational diabetes (GDM)** are at significantly increased risk for Type 2 diabetes and qualify for the **NHS Diabetes Prevention Programme (NDPP)** regardless of whether their current results show non-diabetic hyperglycaemia. - Despite her **HbA1c being 41 mmol/mol** (below the pre-diabetes threshold of 42) and normal fasting glucose, her multiple risk factors including **obesity (BMI 38)**, **PCOS**, and recurrent GDM necessitate intensive lifestyle intervention. *Low risk; continue lifestyle advice and screen for diabetes every 3 years* - This patient is not low risk; a history of **gestational diabetes** carries a seven-fold lifetime risk of developing Type 2 diabetes and classifies her as high risk. - Screening every 3 years is insufficient; patients with previous GDM require **annual HbA1c monitoring** for life according to guidelines. *Moderate risk; arrange annual HbA1c monitoring* - While annual monitoring is correct for someone with a history of GDM, classifying her as only "moderate risk" and omitting referral to an **intensive lifestyle intervention** (NDPP) ignores her substantial cumulative risk factors. - This approach fails to provide the most effective preventive strategy by not addressing her **obesity** and **PCOS comorbidities** aggressively. *Very high risk; commence metformin for diabetes prevention* - **Metformin** is generally reserved for patients where lifestyle interventions have failed, or who have rising **HbA1c levels** within the pre-diabetic range (42-47 mmol/mol), or specific high-risk groups. - Current clinical guidelines prioritise **structured lifestyle programmes** (diet and physical activity) over pharmacological intervention for initial primary prevention. *Diabetes likely given risk factors; arrange oral glucose tolerance test* - Her **HbA1c (41 mmol/mol)** and **fasting glucose (5.8 mmol/L)** are currently within normal ranges, indicating that diabetes is not currently present or "likely" based on these objective measures. - An **Oral Glucose Tolerance Test (OGTT)** is typically used for diagnosing GDM during pregnancy or if results are borderline for diabetes, but it is not the initial preventive management step when current screening results are normal.
Question 76: A 67-year-old woman with type 2 diabetes attends for review. Her diabetic eye screening result indicates 'ungradable images - unable to visualise retina due to cataracts'. The report requests referral to ophthalmology. She mentions her vision has gradually deteriorated but she can still manage daily activities. What is the most appropriate management?
- A. Routine ophthalmology referral for cataract assessment and retinal examination (Correct Answer)
- B. Repeat diabetic eye screening in 3 months after pupil dilation
- C. Urgent ophthalmology referral within 2 weeks due to diabetes
- D. Discharge from diabetic eye screening as cataracts prevent adequate screening
- E. Refer to optometry for refraction and cataract assessment first
Explanation: ***Routine ophthalmology referral for cataract assessment and retinal examination*** - When **diabetic eye screening** images are **ungradable** due to **cataracts**, a **clinical retinal examination** by an ophthalmologist is essential to assess for **diabetic retinopathy**. - The patient's **gradual vision deterioration** and ability to manage daily activities suggest a **routine referral** is appropriate, as there are no signs indicating an urgent, sight-threatening condition like **proliferative diabetic retinopathy**. *Repeat diabetic eye screening in 3 months after pupil dilation* - **Cataracts** cause a physical **media opacity** that typically cannot be overcome by **pupil dilation** alone, making repeat screening unlikely to yield gradable images. - Delaying a proper **ophthalmology assessment** for three months could lead to a missed or progression of **diabetic retinopathy**, which is crucial for early management. *Urgent ophthalmology referral within 2 weeks due to diabetes* - An **urgent referral (within 2 weeks)** is typically reserved for acute, sight-threatening conditions such as **proliferative diabetic retinopathy**, sudden vision loss, or symptoms indicating retinal detachment. - This patient's **gradual vision loss** and stable daily activities, despite ungradable images, do not meet the criteria for an urgent referral pathway. *Discharge from diabetic eye screening as cataracts prevent adequate screening* - Discharging a patient with **diabetes** from **eye screening** is inappropriate as they remain at a high, lifelong risk for developing or progressing **diabetic retinopathy**. - Instead, if digital screening is not possible, the patient should transition to **ophthalmology surveillance** to ensure regular clinical assessment of their retina. *Refer to optometry for refraction and cataract assessment first* - While optometrists can identify **cataracts**, the primary concern following a failed diabetic eye screen is a comprehensive **medical retinal examination** by an ophthalmologist to rule out or manage **diabetic retinopathy**. - A direct **ophthalmology referral** ensures the patient receives the appropriate specialized assessment and management planning, including potential **cataract surgery** to enable future screening.
Question 77: A 35-year-old man presents requesting a general health check. He has no symptoms and takes no regular medication. His father developed hypertension at age 60. The patient runs regularly and maintains a healthy diet. His BMI is 24 kg/m², blood pressure 118/76 mmHg. He asks for blood tests 'to check everything is okay'. What is the most appropriate approach?
- A. Arrange full blood count, renal function, liver function, lipids, HbA1c, and thyroid function
- B. Explain that routine health checks for asymptomatic adults without risk factors are not recommended (Correct Answer)
- C. Offer NHS Health Check as he is over 40 years old
- D. Arrange lipid profile and HbA1c only as these are recommended screening tests
- E. Arrange cardiovascular risk assessment and blood tests if QRISK3 >10%
Explanation: ***Explain that routine health checks for asymptomatic adults without risk factors are not recommended*** - For **asymptomatic adults** under the age of 40 with no significant risk factors, routine "general health checks" or a battery of screening blood tests are not supported by **evidence-based guidelines**. - Indiscriminate testing in low-risk individuals can lead to **overdiagnosis**, false positives, and unnecessary patient anxiety without providing a clear clinical benefit. *Arrange full blood count, renal function, liver function, lipids, HbA1c, and thyroid function* - Performing a broad panel of tests in this patient would violate **stewardship of resources** and increase the risk of finding clinically insignificant abnormalities. - There is no clinical indication for **FBC, LFTs, or TFTs** in an asymptomatic 35-year-old with a healthy lifestyle and normal BMI. *Offer NHS Health Check as he is over 40 years old* - The **NHS Health Check** program is specifically designed for adults aged **40 to 74 years**; this patient is only 35 years old and therefore ineligible. - The patient's father developed hypertension at 60, which does not count as **premature cardiovascular disease** (usually defined as occurring before age 60), thus not triggering early screening. *Arrange lipid profile and HbA1c only as these are recommended screening tests* - Lipids and HbA1c are not recommended as **universal screening tools** for healthy, normotensive 35-year-olds without secondary risk factors like obesity or high-risk ethnicity. - Screening for **Type 2 Diabetes** and dyslipidemia in the UK is primarily delivered via the targeted **NHS Health Check** for patients 40 and over. *Arrange cardiovascular risk assessment and blood tests if QRISK3 >10%* - Primary prevention **QRISK3 assessment** is typically indicated for patients aged 40 to 84 or those with specific risk factors such as **Type 1 Diabetes** or chronic kidney disease. - Since the patient is only 35 and has a **healthy BMI** and normal blood pressure, a formal QRISK3 calculation is not routinely required or indicated.
Question 78: A 49-year-old woman attends for discussion about her recent NHS breast screening mammogram which showed scattered fibroglandular densities. She has read online that dense breast tissue increases cancer risk and asks whether she needs additional screening with ultrasound or MRI. What is the most appropriate response based on current NHS screening policy?
- A. Arrange supplemental breast ultrasound at next screening in 3 years
- B. Refer for breast MRI screening if she has additional risk factors
- C. Explain that breast density does not affect cancer risk, only mammogram interpretation
- D. Reassure that standard mammographic screening remains appropriate; supplemental imaging is not routinely offered based on density alone (Correct Answer)
- E. Advise annual mammography instead of 3-yearly due to increased density
Explanation: ***Reassure that standard mammographic screening remains appropriate; supplemental imaging is not routinely offered based on density alone***- Under current **NHS Breast Screening Programme (NHSBSP)** policy, breast density is not used as a standalone criterion for supplemental screening with ultrasound or MRI.- While dense tissue can mask lesions, evidence does not yet support that additional screening based on density alone improves **mortality outcomes** within the UK population screening model.*Arrange supplemental breast ultrasound at next screening in 3 years*- Routine **supplemental ultrasound** is not provided by the NHS for high-density tissue due to concerns regarding a high rate of **false positives**.- The priority remains the **standard 3-yearly mammogram** unless the patient is classified within a specific high-risk group (e.g., genetic predisposition).*Refer for breast MRI screening if she has additional risk factors*- In the UK, **MRI screening** is strictly reserved for women with a very high lifetime risk (often >30%), such as **BRCA gene carriers** or those with a very strong family history.- Finding **scattered fibroglandular densities** on a mammogram does not trigger an MRI referral without these specific high-risk genetic or hereditary markers.*Explain that breast density does not affect cancer risk, only mammogram interpretation*- This statement is medically incorrect: increased breast density is an **independent risk factor** for developing breast cancer, not just a diagnostic challenge.- It also creates a **masking effect** where white dense tissue can hide white cancerous lesions, making mammograms harder to interpret.*Advise annual mammography instead of 3-yearly due to increased density*- The **NHSBSP** follows a fixed interval of **every 3 years** for women aged 50-70; there is no current provision to increase frequency based on tissue density.- **Annual mammography** is typically reserved for women under 50 who are at increased risk due to family history, rather than density findings in the screening age group.
Question 79: A 52-year-old woman of South Asian ethnicity attends for her NHS Health Check. She has a BMI of 26 kg/m², waist circumference 82 cm, blood pressure 128/78 mmHg, fasting glucose 6.3 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.1 mmol/L. She has no family history of diabetes. What is her diabetes risk status?
- A. Low risk; routine screening in 5 years
- B. Moderate risk; repeat HbA1c annually
- C. High risk (non-diabetic hyperglycaemia); intensive lifestyle intervention required (Correct Answer)
- D. Diabetes diagnosed; commence metformin
- E. Impaired fasting glucose only; dietary advice and repeat in 3 years
Explanation: ***High risk (non-diabetic hyperglycaemia); intensive lifestyle intervention required***- The patient's **fasting glucose of 6.3 mmol/L** and **HbA1c of 43 mmol/mol** both fall into the range for **non-diabetic hyperglycaemia (NDH)** or pre-diabetes (fasting glucose 6.1-6.9 mmol/L; HbA1c 42-47 mmol/mol).- Given her **South Asian ethnicity** and elevated **waist circumference (82 cm)**, she is at **high risk** of progressing to Type 2 diabetes, necessitating a referral to an **intensive lifestyle intervention program** such as the NHS Diabetes Prevention Programme.*Low risk; routine screening in 5 years*- Her elevated **fasting glucose (6.3 mmol/L)** and **HbA1c (43 mmol/mol)**, along with her ethnicity and waist circumference, indicate a **significant risk** for diabetes, not a low risk.- **Routine screening in 5 years** is insufficient for someone already showing signs of non-diabetic hyperglycaemia and multiple risk factors.*Moderate risk; repeat HbA1c annually*- While annual HbA1c monitoring is appropriate for NDH, this patient's glycemic values and risk factors (ethnicity, waist circumference) categorize her as **high risk**, which warrants a more active intervention than just monitoring.-
Question 80: A 66-year-old man has completed 12 weeks of varenicline for smoking cessation and reports being smoke-free for 10 weeks. He works as a long-distance lorry driver and is concerned about weight gain since quitting (he has gained 4 kg). He requests to continue varenicline for another 12 weeks to prevent relapse. What is the most appropriate response?
- A. Decline extension as standard course is 12 weeks and he has achieved abstinence
- B. Prescribe additional 12 weeks of varenicline as relapse prevention in successful quitters (Correct Answer)
- C. Switch to nicotine replacement therapy for ongoing maintenance
- D. Prescribe orlistat to address weight gain concerns
- E. Offer bupropion as alternative to limit post-cessation weight gain
Explanation: ***Prescribe additional 12 weeks of varenicline as relapse prevention in successful quitters*** - According to **NICE guidelines**, patients who have successfully quit smoking after a 12-week course can be offered an additional 12-week course to further reduce the risk of **relapse**. - This patient's concern about **weight gain** and his occupation as a long-distance lorry driver suggest potential triggers for relapse, making extended therapy a clinically sound strategy for long-term **abstinence**. *Decline extension as standard course is 12 weeks and he has achieved abstinence* - While 12 weeks is the standard initial treatment, **NICE guidelines** explicitly support extending varenicline for an additional 12 weeks in **successful quitters** to consolidate the quit attempt. - Declining the request would ignore the patient's expressed concerns about **relapse** and miss an opportunity to enhance long-term cessation success. *Switch to nicotine replacement therapy for ongoing maintenance* - There is no clinical reason to switch to **Nicotine Replacement Therapy (NRT)** when the patient has successfully quit smoking and is tolerating **varenicline** well. - **Varenicline** is a **partial agonist** at the α4β2 nicotinic receptor and is often more effective than NRT monotherapy for maintaining **abstinence**. *Prescribe orlistat to address weight gain concerns* - A **weight gain of 4 kg** is a common and expected side effect of smoking cessation and does not typically meet the criteria for **orlistat**, which is reserved for individuals with a **BMI of 30 kg/m² or higher** (or 27 kg/m² with comorbidities). - The primary focus remains on maintaining **smoking abstinence**, as the health benefits of quitting far outweigh the minor risk associated with modest post-cessation weight gain. *Offer bupropion as alternative to limit post-cessation weight gain* - While **bupropion** can help attenuate post-cessation weight gain, it is inappropriate to switch medications when a patient has successfully quit with **varenicline**. - Introducing a new drug would expose the patient to a different **side effect profile** and contraindications without demonstrating superior efficacy for relapse prevention in this already successful quitter.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free